Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 28 - Studien 271 bis 280 von insgesamt 330
- Rekrutierung läuftQualitätssicherung der Therapie des Ovarialkarzinoms (QS-OVAR)DRKS00027253DRKS00027253DRKS00027253
- Rekrutierung läuftErhebung Ovarialmalignom (QS-OVAR 2025)
- Rekrutierung läuftEvaluation of Clinical Management and Outcome in High Risk or Recurrent Endometrial Cancer - A Real-World Observational Study (QS-Endometrium)RETROSPEKTIV
- Rekrutierung läuftEvaluation of Clinical Management and Outcome in High-Risk or Recurrent Endometrial Cancer - A Real-World Observational Study (QS-Endometrium)RETROSPEKTIV
- Rekrutierung läuftQualitätssicherung Ovarialmalignom 2025
- Rekrutierung läuftA Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases
- Rekrutierung läuftR-Pola-Glo – A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOPMolekulare Marker
- Rekrutierung läuftA PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
- Rekrutierung läuft
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphom
- Rekrutierung läuftRadical antegrade modular pancreatosplenectomy versus conventionaldistal pancreatosplenectomy for pancreatic cancer – The multicenter,randomized controlled RAMPS-Trial